Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Goal Management Training (GMT) for Acquired Brain Injury (Including Stroke)

Executive functions help people initiate, organize, monitor, and complete everyday activities. Difficulties with these functions are common after acquired brain injury and may also occur in people with long-term pain.

Official registry: https://clinicaltrials.gov/study/NCT07924774 · Karolinska Institutet · enrollment listed as 120

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Goal Management Training (GMT). The registry lists allocation as randomized. Executive functions help people initiate, organize, monitor, and complete everyday activities.

They plan to enroll about 120 people at 3 sites. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

Cognitive Rehabilitation of Executive Dysfunction With the Goal Management Training (GMT) - Exploring Variations in Mode of Administration, Frequency and Intensity.

Interventions: Goal Management Training (GMT)

Primary outcome (registry wording): Change following Goal Management Training in participant-reported everyday executive difficulties over the follow-up period measured with the Dysexecutive Questionnaire (DEX)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 67 Years
  • who can join meeting either of the following clinical profiles:
  • 1 a) Acquired brain injury (ABI) with an indicated need for rehabilitation and presenting with self-reported and/or test-verified executive dysfunction or working memory deficits
  • 1 b) Referred to the Pain Section at the Regional University Hospital (RUS) for standard pain rehabilitation and presenting with self-reported and/or test-verified executive dysfunction or working memory deficits
  • 2\. Aged between 18 and 67 years. 3. Participating in team-based rehabilitation at one of the participating multicenter sites
  • The intervention requires at least moderate illness insight, some awareness of how difficulties manifest in daily life, and adequate memory retention to learn and generalize strategies outside of session. Consequently, the following

Public study contact (from the registry)

Gabriela Markovic, PhD

0046707777452

gabriela.markovic@ki.se

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

3 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07924774 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07924774?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07924774?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary